At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
olaparib +2 moredrug
Likely dose
olaparib 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
In Brief
A Phase 2 clinical trial evaluating olaparib, paclitaxel, and 1 other intervention for Gastric Cancer. Completed, enrolled 124 participants across 7 sites.
Detailed Summary
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedFeb 2010
Primary CompletionMay 2012
Study CompletionJun 2023
TodayJul 2026
First PostedFeb 5, 2010
Enrollment StartFeb 2, 2010
Primary CompletionMay 11, 2012
Study CompletionJun 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.4 years ago
Interventions
olaparibdrug
100mg BID oral tablet continuous
paclitaxeldrug
iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
Placebodrug
100mg BID oral tablet to match olaparib tablet